Prenatal Cannabis Use Tied to Adverse Maternal Health Outcomes
By Lori Solomon HealthDay Reporter
THURSDAY, July 25, 2024 -- Prenatal cannabis use is associated with several adverse maternal health outcomes during pregnancy, according to a study published July 22 in JAMA Internal Medicine.
Kelly C. Young-Wolff, Ph.D., from Kaiser Permanente Northern California in Oakland, and colleagues evaluated whether prenatal cannabis use (self-reported use during early pregnancy or a positive toxicology test result based on universal screening) is associated with maternal health outcomes during pregnancy. Analysis included 316,722 pregnancies (January 2011 to December 2019) among 250,221 unique individuals.
The researchers found that 6.3 percent of individuals screened positive for prenatal cannabis use (2.9 percent by self-report, 5.3 percent by toxicology testing, and 1.8 percent by both). Cannabis use frequency was daily for 0.6 percent, weekly for 0.7 percent, monthly or less for 1.5 percent, and unknown for 3.4 percent. Greater risk of gestational hypertension (adjusted risk ratio [aRR], 1.17), preeclampsia (aRR, 1.08), weight gain less than guidelines (aRR, 1.05), weight gain greater than guidelines (aRR, 1.09), and placental abruption (aRR, 1.19) were associated with prenatal cannabis use. Similar results were seen for use determined by self-report only or toxicology testing only.
"Continued research is needed to understand whether characteristics of prenatal cannabis use (e.g., dose, mode, and timing) moderate these associations," the authors write.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
No Increase Seen in Neurodevelopmental Disorders With Prenatal Triptan Use
WEDNESDAY, May 21, 2025 -- Children prenatally exposed to different triptan intensities and duration, alone or in combination with other preventive medications for migraine, do...
Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk
TUESDAY, May 20, 2025 -- Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published...
USPSTF Continues to Recommend Syphilis Screening Early in Pregnancy
TUESDAY, May 13, 2025 -- The U.S. Preventive Services Task Force (USPSTF) recommends screening for syphilis during pregnancy. This recommendation forms the basis of a final...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.